These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18090222)

  • 1. Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control.
    Urbano N; Modoni S
    Nucl Med Commun; 2007 Dec; 28(12):943-50. PubMed ID: 18090222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of techniques for analysing 90Y-Zevalin thin-layer chromatography plates.
    O'Brien LM; Waight CC; Millar AM
    Nucl Med Commun; 2005 Feb; 26(2):163-6. PubMed ID: 15657511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States.
    Schultz MK; Cessna JT; Anderson TL; Ponto JA; Petry N; Kowalsky RJ; Palmer MR; Beinlich UF; Baker W; Hinkle GH; Hung JC; Quinton T; Rice PA; Divgi C; Norenberg JP
    Appl Radiat Isot; 2008 Feb; 66(2):252-60. PubMed ID: 17933545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan.
    Siegel JA; Zimmerman BE; Kodimer K; Dell MA; Simon WE
    J Nucl Med; 2004 Mar; 45(3):450-4. PubMed ID: 15001686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
    Grillo-López AJ
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National intercomparison program for radiopharmaceutical activity measurements.
    dos Santos JA; Iwahara A; de Oliveira AE; da Silva MA; da Silva CJ; Tauhata L; Lopes RT
    Appl Radiat Isot; 2004; 60(2-4):523-7. PubMed ID: 14987696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
    Wiseman GA; Witzig TE
    Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity measurements with radionuclide calibrators in the Czech Republic.
    Olsovcová V
    Appl Radiat Isot; 2004; 60(2-4):535-8. PubMed ID: 14987698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin).
    Papi S; Martano L; Garaboldi L; Rossi A; Cremonesi M; Grana CM; Paolucci D; Sansovini M; Paganelli G; Chinol M
    Nucl Med Biol; 2010 Jan; 37(1):85-93. PubMed ID: 20122673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer standard for beta decay radionuclides in radiotherapy.
    Thieme K; Beinlich U; Fritz E
    Appl Radiat Isot; 2004; 60(2-4):519-22. PubMed ID: 14987695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing equivalence for activity standards of short-lived radionuclides using the NPL secondary standard radionuclide calibrator.
    Woods MJ; Baker M
    Appl Radiat Isot; 2004; 60(2-4):499-504. PubMed ID: 14987692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
    Theuer CP; Leigh BR; Multani PS; Allen RS; Liang BC
    Biotechnol Annu Rev; 2004; 10():265-95. PubMed ID: 15504711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
    Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
    J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.